Stages of hair loss follow a gradual, recognisable pattern that can unfold over months or years, making early identification essential for effective management. Whether you are noticing subtle temple recession, a widening parting, or patchy shedding, understanding where you are in the progression helps determine the most appropriate course of action. This article explains how hair loss develops, the clinical scales used in the UK to classify it, common causes at each stage, when to seek NHS advice, and the treatment options available — from over-the-counter minoxidil to specialist-initiated therapies for severe alopecia areata.

How Hair Loss Progresses: An Overview of the Stages

Hair loss most commonly progresses gradually through disruption of the hair growth cycle, with androgenetic alopecia causing follicular miniaturisation and telogen effluvium causing temporary diffuse shedding that typically resolves within three to six months.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss rarely occurs overnight. In most cases, it follows a gradual, recognisable pattern that unfolds over months or years. Understanding how hair loss progresses can help individuals identify changes early and seek appropriate advice before significant thinning becomes established.

The hair growth cycle consists of three main phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). In healthy hair, around 85–90% of follicles are in the anagen phase at any one time. When this balance is disrupted — whether through genetics, hormonal changes, or illness — more follicles shift prematurely into the telogen phase, resulting in increased shedding and reduced density.

In androgenetic alopecia (the most common form), progression typically begins with subtle recession at the temples or diffuse thinning at the crown. Over time, affected follicles miniaturise, producing progressively finer, shorter (vellus-like) hairs; the follicles themselves often persist in a miniaturised state rather than being entirely lost. In women, the pattern tends to differ, with diffuse thinning across the top of the scalp rather than a receding hairline.

It is important to note that not all hair loss is permanent or progressive. Telogen effluvium — often triggered by physical or emotional stress, surgery, childbirth, rapid weight loss, or illness — can cause widespread shedding that typically begins two to three months after the trigger and improves within three to six months once the underlying cause is addressed. Postpartum telogen effluvium is a particularly common and self-limiting pattern. A chronic form can persist for longer and may warrant further investigation. Recognising the difference between temporary and progressive hair loss is a key first step in determining the most appropriate course of action.

Sources: NHS Hair loss; British Association of Dermatologists (BAD) patient information on male and female pattern hair loss.

Recognised Classification Scales Used in the UK

UK clinicians use the Norwood-Hamilton Scale (seven stages) for male-pattern hair loss and the Ludwig Scale (three grades) for female-pattern hair loss, alongside the SALT score for alopecia areata in specialist settings.

Clinicians in the UK use commonly used classification systems to assess and document the stages of hair loss objectively. These scales provide a shared language for diagnosis, treatment planning, and monitoring response to therapy.

The Norwood-Hamilton Scale is the most widely used tool for classifying male-pattern hair loss (androgenetic alopecia in men). It describes seven stages, ranging from Stage I (minimal or no recession) through to Stage VII (extensive loss confined to a band of hair around the sides and back of the scalp). Intermediate stages — particularly IIa, IIIa, IVa, and Va — capture variations in the pattern of recession versus crown thinning.

For women, the Ludwig Scale is the standard classification tool. It identifies three grades of female-pattern hair loss:

• Grade I: Mild thinning at the crown, often concealed by existing hair

• Grade II: Noticeable widening of the central parting with reduced density

• Grade III: Severe diffuse thinning across the top of the scalp, with the frontal hairline typically preserved

The Sinclair Scale is an alternative five-point grading system for women that some UK dermatologists prefer for its clinical simplicity. The Savin Scale incorporates assessment of overall density and is sometimes used in research settings.

For alopecia areata, the SALT score (Severity of Alopecia Tool) is used in specialist settings to quantify the percentage of scalp hair loss, which is particularly important when assessing eligibility for newer treatments.

These classification tools guide treatment decisions and help clinicians determine whether intervention is likely to be beneficial. A dermatologist will typically use one of these scales alongside a clinical history, dermoscopy, and sometimes blood tests to reach a comprehensive assessment. NHS referrals for hair loss are made to dermatology ; trichologists are non-medical practitioners who work in private practice and are not part of NHS referral pathways.

Sources: NICE CKS: Alopecia areata; BAD patient information: Male pattern hair loss, Female pattern hair loss, Alopecia areata.

Common Causes at Each Stage of Hair Loss

Early-stage loss is most often caused by androgenetic alopecia or telogen effluvium, while advanced stages may reflect long-standing follicular miniaturisation or scarring alopecias such as lichen planopilaris, which require urgent specialist assessment.

The underlying cause of hair loss can vary considerably depending on the stage at which it presents, the pattern observed, and the individual's broader health history. Identifying the cause is essential, as it directly influences management.

Early-stage hair loss (e.g., Norwood I–II or Ludwig Grade I) is frequently attributable to:

• Androgenetic alopecia: Driven by genetic sensitivity to dihydrotestosterone (DHT), which causes follicular miniaturisation

• Telogen effluvium: A reactive, diffuse shedding often following physical or emotional stress, surgery, childbirth, or rapid weight loss

• Nutritional deficiencies: Low ferritin is the most commonly assessed micronutrient in clinical practice; other deficiencies (such as vitamin D or zinc) are considered on a case-by-case basis depending on history and examination, rather than tested routinely

• Traction alopecia: Caused by prolonged tension on the hair from tight hairstyles; early recognition and change in hair practice can prevent permanent loss

• Tinea capitis: A fungal scalp infection that can cause patchy hair loss, particularly in children; prompt diagnosis and antifungal treatment are important to prevent scarring

Mid-stage hair loss may reflect ongoing androgenetic alopecia, but clinicians should also consider:

• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism can cause diffuse thinning

• Alopecia areata: An autoimmune condition causing patchy loss that can progress to more extensive involvement

• Scalp conditions: Seborrhoeic dermatitis or psoriasis may exacerbate underlying hair loss

Advanced-stage hair loss is most commonly the result of long-standing androgenetic alopecia, where follicular miniaturisation has become extensive. However, scarring alopecias — such as lichen planopilaris or frontal fibrosing alopecia — can also produce permanent loss and require prompt specialist assessment, as early treatment can limit further damage.

Certain medicines are also recognised causes of hair loss at any stage. Examples include anticoagulants (e.g., warfarin), retinoids (e.g., isotretinoin), antithyroid agents (e.g., carbimazole), and beta-blockers. Individual product SmPCs (available via the electronic Medicines Compendium, emc) and the BNF provide authoritative information on medicine-related hair loss. If a medicine is suspected as a cause, patients should consult their GP before making any changes to their prescription. Suspected adverse drug reactions can be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Sources: NICE CKS: Male pattern hair loss, Female pattern hair loss, Diffuse hair loss, Alopecia areata, Tinea capitis; NHS Hair loss; BAD patient information: Lichen planopilaris, Frontal fibrosing alopecia; BNF; emc SmPCs.

When to See a GP or NHS Specialist

You should see your GP promptly if hair loss is sudden, patchy, associated with scalp symptoms, or accompanied by systemic symptoms such as fatigue or weight changes, as early assessment can identify treatable causes and prevent irreversible loss.

Many people experiencing hair loss delay seeking medical advice, either assuming it is a normal part of ageing or feeling uncertain whether it warrants clinical attention. However, early assessment can make a meaningful difference — particularly when a treatable underlying cause is present or when progression can be slowed with timely intervention.

You should contact your GP if you notice:

• Sudden or rapid hair loss over a period of weeks

• Patchy or irregular areas of loss, or hair coming out in clumps

• Associated scalp symptoms such as itching, burning, scaling, or pain

• Hair loss accompanied by other symptoms such as fatigue, unexplained weight changes, or irregular periods

• Loss of eyebrows, eyelashes, or body hair alongside scalp hair

• Significant distress related to hair loss

Your GP will typically take a detailed history and may arrange blood tests to exclude systemic causes. First-line investigations usually include a full blood count (FBC), thyroid function tests (TFTs), and serum ferritin. If there are clinical features suggesting hyperandrogenism or polycystic ovary syndrome (PCOS) — such as irregular periods, acne, or hirsutism — hormonal tests including androgens and prolactin may also be appropriate. Vitamin D, zinc, and other micronutrients are tested selectively based on clinical history rather than routinely. If an underlying condition is identified, treating it often leads to partial or full hair regrowth.

If no systemic cause is found and the pattern is consistent with androgenetic alopecia, your GP may initiate treatment or refer you to an NHS dermatologist. Referral to dermatology is particularly important — and should be made promptly — when scarring alopecia, tinea capitis, or rapidly progressive alopecia areata is suspected, as early treatment can prevent irreversible follicular damage. Children with patchy or inflammatory hair loss should be assessed promptly. NICE CKS guidance supports a structured approach to investigation before initiating long-term treatment.

Sources: NHS Hair loss: When to see a GP; NICE CKS: Male pattern hair loss, Female pattern hair loss, Alopecia areata, Tinea capitis.

Treatment Options Available at Different Stages

Treatment is most effective at early stages; licensed options include topical minoxidil and prescription finasteride for androgenetic alopecia, while severe alopecia areata may be treated with MHRA-authorised JAK inhibitors under specialist supervision.

The range of effective treatments for hair loss has expanded considerably, though the appropriateness of each option depends on the stage of loss, the underlying cause, and the individual's preferences and medical history.

At early stages, treatment is most likely to be effective, as follicles remain active and miniaturisation is not yet complete:

• Minoxidil (topical): A vasodilator that prolongs the anagen phase and increases follicular size. Available over the counter in 2% and 5% formulations; it is licensed for androgenetic alopecia in both men and women and is one of the most evidence-based options available. Common side effects include scalp irritation and initial increased shedding.

• Minoxidil (low-dose oral): Oral minoxidil is a prescription-only medicine (POM) and is not licensed for hair loss in the UK — its use for this indication is off-label. It may be considered by experienced prescribers in selected cases. Potential adverse effects include fluid retention, unwanted facial hair growth, and cardiovascular effects; appropriate monitoring is required. Patients should discuss the off-label status and risks fully with their prescriber.

• Finasteride (oral, 1 mg daily): A 5-alpha reductase inhibitor that reduces DHT levels, slowing follicular miniaturisation in men. It is prescription-only in the UK. Patients should be aware of important MHRA safety communications: finasteride is associated with a risk of psychiatric side effects (including depression and, rarely, suicidal ideation) and sexual side effects (including decreased libido, erectile dysfunction, and ejaculatory disorders), which may persist after stopping treatment. Prescribers are advised to provide patients with a patient alert card at the time of prescribing. Finasteride can also lower PSA levels, which should be taken into account in prostate cancer screening. Finasteride must not be used by women who are pregnant or may become pregnant, and women should not handle crushed or broken tablets due to the risk of absorption and teratogenic harm. Shared decision-making is essential before starting treatment.

• Addressing nutritional deficiencies: Correcting confirmed low ferritin through dietary change or supplementation can support regrowth where deficiency is a contributing factor.

At mid-to-advanced stages, options become more limited but remain worthwhile:

• Combination therapy (topical minoxidil plus finasteride) may offer greater benefit than either agent alone in men with androgenetic alopecia.

• Low-level laser therapy (LLLT): Evidence is mixed and of variable quality. There is no formal NICE guidance recommending LLLT for hair loss, and it is not routinely commissioned on the NHS. It may be considered as an adjunct by some specialists, but patients should be aware of the limited evidence base.

• Hair transplant surgery: Follicular unit transplantation (FUT) or follicular unit extraction (FUE) can restore hair in areas of permanent loss. Hair transplantation is not routinely available on the NHS and is usually accessed privately. Patients should ensure any provider is registered with the Care Quality Commission (CQC) and that a thorough suitability assessment is carried out beforehand, as donor hair availability limits its use in advanced stages.

• Off-label options: Spironolactone (in women) and dutasteride (in men) are sometimes used off-label for androgenetic alopecia under specialist or experienced prescriber supervision, with appropriate monitoring.

For alopecia areata, treatments include topical or intralesional corticosteroids and immunotherapy. More recently, JAK inhibitors — specifically baricitinib (Olumiant), authorised by the MHRA and EMA for severe alopecia areata, and ritlecitinib (Litfulo), also EMA-authorised — represent significant advances for severe or refractory cases. These are specialist-initiated treatments requiring careful patient selection and safety monitoring, including assessment for serious infections, venous thromboembolism (VTE), and relevant laboratory parameters. They are not suitable for use in pregnancy. Patients should refer to current NICE technology appraisal guidance and their specialist for up-to-date access and eligibility information.

Suspected side effects from any medicine used for hair loss should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Experiencing these side effects? Our pharmacists can help you navigate them →

Sources: emc SmPCs: Minoxidil topical (Regaine 2%/5%), Finasteride 1 mg, Baricitinib (Olumiant), Ritlecitinib (Litfulo); MHRA Drug Safety Update: Finasteride — risk of psychiatric and sexual side effects and advice to provide a patient alert card; NICE Technology Appraisal: Baricitinib for severe alopecia areata; EMA EPARs: Baricitinib, Ritlecitinib; NHS: Hair transplant surgery; MHRA Yellow Card Scheme.

Slowing Progression and Managing Hair Loss Long-Term

Consistent use of minoxidil or finasteride is essential, as stopping treatment typically leads to resumed hair loss within 6–12 months; a balanced diet, stress management, and regular GP or dermatology follow-up support long-term outcomes.

While not all hair loss can be reversed, there is good evidence that progression can be meaningfully slowed with consistent management and appropriate lifestyle measures. Long-term success depends on adherence to treatment, regular monitoring, and realistic expectations.

Consistency is critical. Both minoxidil and finasteride require continuous use to maintain their effects — stopping treatment typically results in a return to the pre-treatment rate of loss within 6–12 months. Patients should be counselled about this before starting, to support informed decision-making and long-term adherence.

Lifestyle and nutritional factors play a supporting role:

• A balanced diet rich in protein and a variety of micronutrients supports healthy hair cycling. Supplementation should only be considered where a deficiency has been confirmed by a clinician — routine supplementation with biotin, zinc, or vitamin D is not recommended without evidence of deficiency. It is also important to note that high-dose biotin (vitamin B7) supplements can interfere with certain laboratory immunoassays, potentially causing misleading blood test results; patients taking biotin supplements should inform their GP or specialist before blood tests are taken (MHRA Drug Safety Update).

• Avoiding crash dieting or rapid weight loss, which can trigger telogen effluvium.

• Reducing mechanical stress on the hair — such as tight hairstyles, excessive heat styling, or harsh chemical treatments — can minimise additional breakage and reduce the risk of traction alopecia.

• Managing stress through regular physical activity, adequate sleep, and psychological support where needed, as chronic stress is a recognised contributor to hair shedding.

Regular follow-up with a GP or NHS dermatologist allows treatment response to be assessed and adjustments made as needed. Dermoscopy and standardised photography are useful tools for objectively tracking change over time. Trichologists are non-medical practitioners and are not part of NHS follow-up pathways; their services are usually accessed privately.

Finally, it is worth acknowledging the psychological impact of hair loss, which can be significant regardless of the clinical stage. NHS Talking Therapies and support organisations such as Alopecia UK offer valuable resources for those struggling with the emotional aspects of hair loss. Addressing both the physical and psychological dimensions leads to the most holistic and effective long-term management.

Sources: MHRA Drug Safety Update: Biotin (vitamin B7) interference with laboratory tests; NHS guidance on diet and hair health; Alopecia UK; NHS Talking Therapies; NICE CKS: Male pattern hair loss, Female pattern hair loss.

Frequently Asked Questions